OrthoPediatrics Corp. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the Securities and Exchange Commission on October 28, 2026, reporting third-quarter net revenue of $72,661 thousand and a continued operating loss.

Key Highlights

  • Net revenue of $72,661 thousand for the three months ended September 30, 2026, compared to $61,250 thousand in the same period of 2025, according to the filing.
  • Operating loss of $4,225 thousand for Q3 2026, an improvement from an operating loss of $9,428 thousand in Q3 2025, the filing reported.
  • Nine-month net revenue of $202,530 thousand for the period ended September 30, 2026, versus $174,743 thousand for the same period in 2025.
  • Accumulated deficit of $298,992 thousand as of September 30, 2026, up from $275,212 thousand at December 31, 2025, per the filing.
  • Total assets of $509,087 thousand as of September 30, 2026, compared to $508,630 thousand at December 31, 2025.
  • 26,110,476 shares of common stock outstanding as of October 27, 2026, the filing disclosed.
  • Goodwill increased to $118,586 thousand as of September 30, 2026, from $109,269 thousand at December 31, 2025.

OrthoPediatrics Q3 2026 Financial Results and Balance Sheet Position

OrthoPediatrics Corp. (NASDAQ:KIDS), a pediatric orthopedic medical device company headquartered in Warsaw, Indiana, reported net revenue of $72,661 thousand for the three months ended September 30, 2026, according to the filing. Gross profit for the same quarter was $53,976 thousand, compared to $45,274 thousand in Q3 2025. Total operating expenses for Q3 2026 were $58,201 thousand, which included sales and marketing costs of $23,096 thousand, general and administrative expenses of $32,029 thousand, intangible asset impairment of $611 thousand, and research and development costs of $2,465 thousand.

For the nine months ended September 30, 2026, the company reported net revenue of $202,530 thousand and an operating loss of $16,627 thousand, compared to net revenue of $174,743 thousand and an operating loss of $31,066 thousand for the same nine-month period in 2025, the filing stated. Interest expense, net, was $7,248 thousand for the nine months ended September 30, 2026, versus $4,064 thousand in the comparable prior-year period.

On the balance sheet as of September 30, 2026, the company reported total assets of $509,087 thousand, including inventories of $141,864 thousand and accounts receivable of $59,543 thousand, net of allowances of $1,619 thousand. Total liabilities were $169,737 thousand, including a long-term term loan of $48,560 thousand and a long-term convertible note of $48,961 thousand. Total stockholders' equity was $339,350 thousand as of September 30, 2026, down from $346,596 thousand at December 31, 2025, the filing disclosed. The filing also noted a fair value adjustment of contingent consideration of negative $814 thousand in Q3 2026, where no such adjustment was recorded in Q3 2025.

What Was Disclosed

OrthoPediatrics Corp. disclosed its unaudited condensed consolidated financial statements for Q3 2026, covering revenue, operating losses, balance sheet positions, and stockholders' equity changes for the three and nine months ended September 30, 2026.